PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 67% · Mixed 18% · Unfavorable overall 15%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 0.6–1 mg
Reports span 0.05–5 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 62% said they felt similar to their last entry, 41% more positive, and 17% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 33 days · Based on 537 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 63% · Mixed 20% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.01–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 58% said they felt similar to their last entry, 31% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 29 days · Based on 292 repeat reporters
Published sources linked on the BPC-157 and Cerebrolysin wiki pages.
PubMed
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
PubMed
Chang CH, Tsai WC, Lin MS, et al. Molecules. 2019
PubMed
Vukojevic J, Siroglavic M, Kasnik K, et al. Int J Mol Sci. 2022
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Seiwerth S, Rucman R, Turkovic B, et al. Current pharmaceutical design. 2018
PubMed
Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011
PubMed
Lee E, Padgett B. Altern Ther Health Med. 2021
PubMed
Yuan C, Demers A, Silva-Ortiz V, et al. Int J Mol Sci. 2026
PubMed
Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026
PubMed
Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026
PubMed
Chen N, Yang M, Guo J, et al. Cochrane Database Syst Rev. 2017
PubMed
Ziganshina LE, Abakumova T, Nurkhametova D, et al. The Cochrane database of systematic reviews. 2023
PubMed
Ziganshina LE, Abakumova T, Vernay L. The Cochrane database of systematic reviews. 2017